Zoom Technology Group Selects Radisys as Its Technology Partner for Broadband Connectivity Expansion
25.2.2025 15:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, and Zoom Technology Group (ZTG), a fibre network operator with an extensive global network headquartered in Dubai, UAE, announce a strategic collaboration to expand the reach of Fiber-based Broadband Connectivity in the United States based on Radisys’ state-of-the-art Connect Open Broadband portfolio following a successful rollout in South Africa.
Radisys’ leading, cloud-native, modern software implementation-based Connect Open Broadband solutions are designed with open specifications, ensuring seamless interoperability with non-proprietary solutions and fostering an open ecosystem. The competitive, merchant silicon-based portfolio, optimized for the right level of switching, empowers ZTG to reduce both CapEx and OpEx costs by selecting and managing best-in-class broadband solutions that meet their unique network needs – both now and in the future.
Connect Open Broadband’s full-spectrum broadband access portfolio offers open source-based software (Connect Broadband Access Controller, Radisys Management System), interoperable/open optical network terminals (ONTs) and Linux Foundation Broadband’s VOLTHA/SEBA-based optical line terminals (OLTs) that support both G-PON and XGS-PON within the same OLT passive optical network (PON) port without changing or upgrading the PON hardware in the future.
Mohammed Manjra, Founder & CEO, Zoom Technology Group: “Radisys’ products are a game-changer for us as we make our initial foray into the United States market. Their commitment to open, disaggregated broadband solutions delivers the flexibility that will allow us to adapt our architecture as needed in the future. This partnership is a critical step in our global expansion strategy, enabling us to deliver high-speed internet solutions to unserved and underserved communities on a global scale driving inclusive access to bridge the current digital divide that exists in many unserved and underserved communities."
Arpit Joshipura, GM of Networking, IoT & Edge at the Linux Foundation: "The global expansion of VOLTHA underscores the industry's continued shift toward open, disaggregated networks that drive innovation and scalability. As more operators adopt VOLTHA to streamline deployments and enhance interoperability to take advantage of its cost efficiency, flexibility, and faster service delivery, the important role of open standards in next-gen access networks is further reinforced."
Arun Bhikshesvaran, CEO, Radisys: “We are thrilled to have been chosen by ZTG to power their broadband business in the United States following the rollout in South Africa. Our commitment to open standards and systems is further reinforced with this milestone. This also marks a significant expansion of our VOLTHA/SEBA-based solutions into the Americas region following scaled implementations in Asia and Europe.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
About Zoom Technology Group
With over 3 decades of experience in delivering high-speed broadband infrastructure access globally, Zoom Technology Group is committed to driving positive change through innovative solutions within the communities we serve. The group currently owns, operates and manages over 21 million feet of infrastructure and has expanded to 10 offices globally servicing over 77 000 active residential and commercial subscribers. Over the next 5 years we intend expanding the infrastructure to 257 million feet whilst delivering services to over 2.7 million end points.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225705359/en/
Contacts
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom